Bousquet, P. A.
Meltzer, S.
Fuglestad, A. J.
Lüders, T.
Esbensen, Y.
Juul, H. V.
Johansen, C.
Lyckander, L. G.
Bjørnetrø, T.
Inderberg, E. M.
Kersten, C.
Redalen, K. R.
Ree, A. H. http://orcid.org/0000-0002-8264-3223
Funding for this research was provided by:
Kreftforeningen (5740692)
Helse Sør-Øst RHF (2018054, 2019109)
University of Oslo
Article History
Received: 13 October 2021
Accepted: 9 December 2021
First Online: 27 December 2021
Declarations
:
: PAB, SM, TB, KRR, and AHR have submitted two patent applications for diagnostic utilisation of whole blood mitochondrial DNA variants in colorectal cancer. All other authors declare no conflicts of interest.
: The study was approved by the Regional Committee for Medical and Health Research Ethics of South-East Norway (reference number REK 2013/152) and the Institutional Review Board (reference number 12-106) and performed in accordance with the Declaration of Helsinki.
: Written informed consent was required for participation.
: All authors have consented to submission of this article for publication.